China Pharma Holdings Stock Analysis

China Stock Analysis Notes

About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.66. Some equities with similar Price to Book (P/B) outperform the market in the long run. China Pharma Holdings recorded a loss per share of 0.69. The entity had not issued any dividends in recent years. The firm had 1:5 split on the 6th of March 2024. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the Peoples Republic of China. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the Peoples Republic of China. China Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 236 people. For more info on China Pharma Holdings please contact Zhilin Li at 86 89 8668 11730 or go to https://www.chinapharmaholdings.com.

China Pharma Holdings Investment Alerts

China Pharma Holdings Upcoming and Recent Events

China Largest EPS Surprises

View All Earnings Estimates

China Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.69 M.

China Profitablity

The company has Profit Margin (PM) of (0.7) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.5) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.5.

Management Efficiency

China Pharma Holdings has return on total asset (ROA) of (0.1754) % which means that it has lost $0.1754 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7489) %, meaning that it created substantial loss on money invested by shareholders. China Pharma's management efficiency ratios could be used to measure how well China Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.24. The China Pharma's current Return On Capital Employed is estimated to increase to -0.27. As of now, China Pharma's Intangible Assets are increasing as compared to previous years. The China Pharma's current Intangibles To Total Assets is estimated to increase to 0.21, while Total Assets are projected to decrease to under 15.6 M.

Technical Drivers

As of the 22nd of November, China Pharma shows the Downside Deviation of 7.67, risk adjusted performance of 0.0176, and Mean Deviation of 4.27. China Pharma Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

China Pharma Holdings Price Movement Analysis

China Pharma Holdings Insider Trading Activities

China Pharma Outstanding Bonds

China Pharma Predictive Daily Indicators

China Pharma Forecast Models

China Pharma's time-series forecasting models are one of many China Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary China Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how China Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling China shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as China Pharma. By using and applying China Stock analysis, traders can create a robust methodology for identifying China entry and exit points for their positions.

When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.